Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Evasins: Tick Salivary Proteins that Inhibit Mammalian Chemokines.

Bhusal RP, Eaton JRO, Chowdhury ST, Power CA, Proudfoot AEI, Stone MJ, Bhattacharya S.

Trends Biochem Sci. 2019 Nov 1. pii: S0968-0004(19)30204-X. doi: 10.1016/j.tibs.2019.10.003. [Epub ahead of print] Review.

PMID:
31679840
2.

David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments.

Bates A, Power CA.

Antibodies (Basel). 2019 Apr 9;8(2). pii: E28. doi: 10.3390/antib8020028. Review.

3.

Assessing the function of pneumococcal neuraminidases NanA, NanB and NanC in in vitro and in vivo lung infection models using monoclonal antibodies.

Janesch P, Rouha H, Badarau A, Stulik L, Mirkina I, Caccamo M, Havlicek K, Maierhofer B, Weber S, Groß K, Steinhäuser J, Zerbs M, Varga C, Dolezilkova I, Maier S, Zauner G, Nielson N, Power CA, Nagy E.

Virulence. 2018;9(1):1521-1538. doi: 10.1080/21505594.2018.1520545.

4.
5.

Endotoxin neutralization by an O-antigen specific monoclonal antibody: A potential novel therapeutic approach against Klebsiella pneumoniae ST258.

Szijártó V, Guachalla LM, Hartl K, Varga C, Badarau A, Mirkina I, Visram ZC, Stulik L, Power CA, Nagy E, Nagy G.

Virulence. 2017 Oct 3;8(7):1203-1215. doi: 10.1080/21505594.2017.1279778. Epub 2017 Jan 19.

6.

Anti-bacterial Monoclonal Antibodies.

Nagy E, Nagy G, Power CA, Badarau A, Szijártó V.

Adv Exp Med Biol. 2017;1053:119-153. doi: 10.1007/978-3-319-72077-7_7. Review.

PMID:
29549638
7.

Evasins: Therapeutic Potential of a New Family of Chemokine-Binding Proteins from Ticks.

Bonvin P, Power CA, Proudfoot AE.

Front Immunol. 2016 Jun 7;7:208. doi: 10.3389/fimmu.2016.00208. eCollection 2016.

8.

Selective Treg reconstitution during lymphopenia normalizes DC costimulation and prevents graft-versus-host disease.

Bolton HA, Zhu E, Terry AM, Guy TV, Koh WP, Tan SY, Power CA, Bertolino P, Lahl K, Sparwasser T, Shklovskaya E, Fazekas de St Groth B.

J Clin Invest. 2015 Sep;125(9):3627-41. doi: 10.1172/JCI76031. Epub 2015 Aug 24.

9.

Targeting chemokines: Pathogens can, why can't we?

Proudfoot AE, Bonvin P, Power CA.

Cytokine. 2015 Aug;74(2):259-67. doi: 10.1016/j.cyto.2015.02.011. Epub 2015 Mar 6. Review.

PMID:
25753743
10.

From bench to bedside: immunotherapy for prostate cancer.

Tse BW, Jovanovic L, Nelson CC, de Souza P, Power CA, Russell PJ.

Biomed Res Int. 2014;2014:981434. doi: 10.1155/2014/981434. Epub 2014 Sep 4. Review.

11.

Identification of the pharmacophore of the CC chemokine-binding proteins Evasin-1 and -4 using phage display.

Bonvin P, Dunn SM, Rousseau F, Dyer DP, Shaw J, Power CA, Handel TM, Proudfoot AE.

J Biol Chem. 2014 Nov 14;289(46):31846-55. doi: 10.1074/jbc.M114.599233. Epub 2014 Sep 29.

12.

A tissue-engineered humanized xenograft model of human breast cancer metastasis to bone.

Thibaudeau L, Taubenberger AV, Holzapfel BM, Quent VM, Fuehrmann T, Hesami P, Brown TD, Dalton PD, Power CA, Hollier BG, Hutmacher DW.

Dis Model Mech. 2014 Feb;7(2):299-309. doi: 10.1242/dmm.014076.

13.

International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.

Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, Horuk R, Sparre-Ulrich AH, Locati M, Luster AD, Mantovani A, Matsushima K, Murphy PM, Nibbs R, Nomiyama H, Power CA, Proudfoot AE, Rosenkilde MM, Rot A, Sozzani S, Thelen M, Yoshie O, Zlotnik A.

Pharmacol Rev. 2013 Nov 11;66(1):1-79. doi: 10.1124/pr.113.007724. Print 2014. Review. Erratum in: Pharmacol Rev. 2014 Apr;66(2):467.

14.

Combination therapy with the histone deacetylase inhibitor LBH589 and radiation is an effective regimen for prostate cancer cells.

Xiao W, Graham PH, Hao J, Chang L, Ni J, Power CA, Dong Q, Kearsley JH, Li Y.

PLoS One. 2013 Aug 26;8(8):e74253. doi: 10.1371/journal.pone.0074253. eCollection 2013.

15.

Evasin-4, a tick-derived chemokine-binding protein with broad selectivity can be modified for use in preclinical disease models.

Déruaz M, Bonvin P, Severin IC, Johnson Z, Krohn S, Power CA, Proudfoot AE.

FEBS J. 2013 Oct;280(19):4876-87. doi: 10.1111/febs.12463. Epub 2013 Aug 23.

16.

The teratogenic effect of dofetilide during rat limb development and association with drug-induced bradycardia and hypoxia in the embryo.

Ritchie HE, Ababneh DH, Oakes DJ, Power CA, Webster WS.

Birth Defects Res B Dev Reprod Toxicol. 2013 Apr;98(2):144-53. doi: 10.1002/bdrb.21050. Epub 2013 Mar 15.

PMID:
23504928
17.

Serological status of Canadian cattle for brucellosis, anaplasmosis, and bluetongue in 2007-2008.

Paré J, Geale DW, Koller-Jones M, Hooper-McGrevy K, Golsteyn-Thomas EJ, Power CA.

Can Vet J. 2012 Sep;53(9):949-56.

18.

In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147.

Hao J, Madigan MC, Khatri A, Power CA, Hung TT, Beretov J, Chang L, Xiao W, Cozzi PJ, Graham PH, Kearsley JH, Li Y.

PLoS One. 2012;7(8):e40716. doi: 10.1371/journal.pone.0040716. Epub 2012 Aug 3.

19.

The CACCC-binding protein KLF3/BKLF represses a subset of KLF1/EKLF target genes and is required for proper erythroid maturation in vivo.

Funnell AP, Norton LJ, Mak KS, Burdach J, Artuz CM, Twine NA, Wilkins MR, Power CA, Hung TT, Perdomo J, Koh P, Bell-Anderson KS, Orkin SH, Fraser ST, Perkins AC, Pearson RC, Crossley M.

Mol Cell Biol. 2012 Aug;32(16):3281-92. doi: 10.1128/MCB.00173-12. Epub 2012 Jun 18.

20.

Properties of 7ND-CCL2 are modulated upon fusion to Fc.

Severin IC, Souza AL, Davis JH, Musolino N, Mack M, Power CA, Proudfoot AE.

Protein Eng Des Sel. 2012 May;25(5):213-22. doi: 10.1093/protein/gzs008. Epub 2012 Mar 2.

PMID:
22388887
21.

CD44 is a biomarker associated with human prostate cancer radiation sensitivity.

Xiao W, Graham PH, Power CA, Hao J, Kearsley JH, Li Y.

Clin Exp Metastasis. 2012 Jan;29(1):1-9. doi: 10.1007/s10585-011-9423-7. Epub 2011 Sep 28.

PMID:
21953074
22.

IL-18 inhibits growth of murine orthotopic prostate carcinomas via both adaptive and innate immune mechanisms.

Tse BW, Russell PJ, Lochner M, Förster I, Power CA.

PLoS One. 2011;6(9):e24241. doi: 10.1371/journal.pone.0024241. Epub 2011 Sep 15.

23.

Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model.

Hung TT, Chan J, Russell PJ, Power CA.

PLoS One. 2011;6(5):e19389. doi: 10.1371/journal.pone.0019389. Epub 2011 May 16.

24.

Extracorporeal membrane oxygenation for critically ill patients with influenza A (H1N1) 2009: a case series.

Power CA, Van Heerden PV, Moxon D, Martindale G, Roberts B.

Crit Care Resusc. 2011 Mar;13(1):38-43.

PMID:
21355828
25.

Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer.

Wang L, Chen H, Liu F, Madigan MC, Power CA, Hao J, Patterson KI, Pourgholami MH, O'Brien PM, Perkins AC, Li Y.

Cancer Lett. 2011 Jan 28;300(2):122-33. doi: 10.1016/j.canlet.2010.09.013. Epub 2010 Nov 13.

PMID:
21075513
26.

Immunization of newborn and adult mice with low numbers of BCG leads to Th1 responses, Th1 imprints and enhanced protection upon BCG challenge.

Kiros TG, Power CA, Wei G, Bretscher PA.

Immunotherapy. 2010 Jan;2(1):25-35. doi: 10.2217/imt.09.80.

PMID:
20635889
27.

CD147/EMMPRIN and CD44 are potential therapeutic targets for metastatic prostate cancer.

Hao JL, Cozzi PJ, Khatri A, Power CA, Li Y.

Curr Cancer Drug Targets. 2010 May;10(3):287-306. Review.

PMID:
20370680
28.

Anti-chemokine small molecule drugs: a promising future?

Proudfoot AE, Power CA, Schwarz MK.

Expert Opin Investig Drugs. 2010 Mar;19(3):345-55. doi: 10.1517/13543780903535867. Review.

PMID:
20113217
29.

Structural basis of chemokine sequestration by a tick chemokine binding protein: the crystal structure of the complex between Evasin-1 and CCL3.

Dias JM, Losberger C, Déruaz M, Power CA, Proudfoot AE, Shaw JP.

PLoS One. 2009 Dec 30;4(12):e8514. doi: 10.1371/journal.pone.0008514.

30.

A novel model of bone-metastatic prostate cancer in immunocompetent mice.

Power CA, Pwint H, Chan J, Cho J, Yu Y, Walsh W, Russell PJ.

Prostate. 2009 Nov 1;69(15):1613-23. doi: 10.1002/pros.21010.

PMID:
19585491
31.

Inhibition of micrometastatic prostate cancer cell spread in animal models by 213Bilabeled multiple targeted alpha radioimmunoconjugates.

Li Y, Song E, Abbas Rizvi SM, Power CA, Beretov J, Raja C, Cozzi PJ, Morgenstern A, Apostolidis C, Allen BJ, Russell PJ.

Clin Cancer Res. 2009 Feb 1;15(3):865-75. doi: 10.1158/1078-0432.CCR-08-1203.

32.

Ticks produce highly selective chemokine binding proteins with antiinflammatory activity.

Déruaz M, Frauenschuh A, Alessandri AL, Dias JM, Coelho FM, Russo RC, Ferreira BR, Graham GJ, Shaw JP, Wells TN, Teixeira MM, Power CA, Proudfoot AE.

J Exp Med. 2008 Sep 1;205(9):2019-31. doi: 10.1084/jem.20072689. Epub 2008 Aug 4.

33.

Molecular cloning and characterization of a highly selective chemokine-binding protein from the tick Rhipicephalus sanguineus.

Frauenschuh A, Power CA, Déruaz M, Ferreira BR, Silva JS, Teixeira MM, Dias JM, Martin T, Wells TN, Proudfoot AE.

J Biol Chem. 2007 Sep 14;282(37):27250-8. Epub 2007 Jul 19.

34.

Control of prostate cancer spheroid growth using 213Bi-labeled multiple targeted alpha radioimmunoconjugates.

Wang J, Abbas Rizvi SM, Madigan MC, Cozzi PJ, Power CA, Qu CF, Morgenstern A, Apostolidis C, Russell PJ, Allen BJ, Li Y.

Prostate. 2006 Dec 1;66(16):1753-67.

PMID:
16955401
35.

Protein therapeutics--lessons learned and a view of the future.

Johnson-Léger C, Power CA, Shomade G, Shaw JP, Proudfoot AE.

Expert Opin Biol Ther. 2006 Jan;6(1):1-7. Review.

PMID:
16370909
36.

Chemokine blockers--therapeutics in the making?

Wells TN, Power CA, Shaw JP, Proudfoot AE.

Trends Pharmacol Sci. 2006 Jan;27(1):41-7. Epub 2005 Nov 28. Review.

PMID:
16310864
37.

Multi-faceted strategies to combat disease by interference with the chemokine system.

Johnson Z, Schwarz M, Power CA, Wells TN, Proudfoot AE.

Trends Immunol. 2005 May;26(5):268-74. Review.

PMID:
15866240
38.

A role for CCR4 in development of mature circulating cutaneous T helper memory cell populations.

Baekkevold ES, Wurbel MA, Kivisäkk P, Wain CM, Power CA, Haraldsen G, Campbell JJ.

J Exp Med. 2005 Apr 4;201(7):1045-51. Epub 2005 Mar 28.

39.

Chemokine inhibition--why, when, where, which and how?

Johnson Z, Power CA, Weiss C, Rintelen F, Ji H, Ruckle T, Camps M, Wells TN, Schwarz MK, Proudfoot AE, Rommel C.

Biochem Soc Trans. 2004 Apr;32(Pt 2):366-77. Review.

PMID:
15046611
40.

Knock out models to dissect chemokine receptor function in vivo.

Power CA.

J Immunol Methods. 2003 Feb;273(1-2):73-82. Review.

PMID:
12535799
41.

Strategies for chemokine antagonists as therapeutics.

Proudfoot AE, Power CA, Rommel C, Wells TN.

Semin Immunol. 2003 Feb;15(1):57-65. Review.

PMID:
12495641
42.

Experimental models linking dendritic cell lineage, phenotype and function.

Fazekas De St Groth B, L Smith A, Bosco J, Sze DM, Power CA, Austen FI.

Immunol Cell Biol. 2002 Oct;80(5):469-76. Review.

PMID:
12225383
43.

Factors that influence T helper cell response to infection.

Power CA.

Curr Opin Infect Dis. 2000 Jun;13(3):209-213.

PMID:
11964788
44.

Vaccination against and treatment of tuberculosis, the leishmaniases and AIDS: perspectives from basic immunology and immunity to chronic intracellular infections.

Bretsche PA, Ismail N, Menon JN, Power CA, Uzonna J, Wei G.

Cell Mol Life Sci. 2001 Nov;58(12-13):1879-96. Review.

PMID:
11766885
45.
46.

The chemokine system: novel broad-spectrum therapeutic targets.

Power CA, Proudfoot AE.

Curr Opin Pharmacol. 2001 Aug;1(4):417-24. Review.

PMID:
11710742
47.

Cellular assays of chemokine receptor activation.

Proudfoot AE, Power CA, Church DJ, Soler D, Mack M.

Curr Protoc Pharmacol. 2001 Nov;Chapter 12:Unit12.4. doi: 10.1002/0471141755.ph1204s14.

PMID:
21959755
48.

A chimeric MIP-1alpha/RANTES protein demonstrates the use of different regions of the RANTES protein to bind and activate its receptors.

Blanpain C, Buser R, Power CA, Edgerton M, Buchanan C, Mack M, Simmons G, Clapham PR, Parmentier M, Proudfoot AE.

J Leukoc Biol. 2001 Jun;69(6):977-85.

PMID:
11404385
49.

The strategy of blocking the chemokine system to combat disease.

Proudfoot AE, Power CA, Wells TN.

Immunol Rev. 2000 Oct;177:246-56. Review.

PMID:
11138781
50.

Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets.

Clemetson KJ, Clemetson JM, Proudfoot AE, Power CA, Baggiolini M, Wells TN.

Blood. 2000 Dec 15;96(13):4046-54.

PMID:
11110672

Supplemental Content

Loading ...
Support Center